[8-K] Celularity Inc. Warrant Reports Material Event
Celularity Inc. entered a Series Seed Preferred Stock Purchase Agreement with Defeye, Inc., receiving 7,198.630 shares of Series Seed-2 Preferred Stock in exchange for $2,890,250 of product purchase credits under their supply and distribution arrangement.
The company also disclosed that Nasdaq notified it of noncompliance for failing to timely file its quarterly report for the period ended March 31, 2025. The company submitted a plan to Nasdaq and was informed it has until August 31, 2025 to file required reports for the periods ended March 31, 2025 and June 30, 2025; failure to meet the exception could lead to delisting, with an appeal available to a Hearings Panel. The filing lists the form of the purchase agreement as Exhibit 10.1 and interactive XBRL cover page as Exhibit 104.
Celularity Inc. ha stipulato un Series Seed Preferred Stock Purchase Agreement con Defeye, Inc., ricevendo 7,198.630 azioni di Series Seed-2 Preferred Stock in cambio di $2,890,250 di crediti per acquisto di prodotto nell'ambito del loro accordo di fornitura e distribuzione.
La società ha inoltre reso noto che Nasdaq l'ha informata della non conformità per il mancato deposito tempestivo del rapporto trimestrale relativo al periodo terminato il 31 marzo 2025. La società ha presentato un piano a Nasdaq e le è stato comunicato che ha tempo fino al 31 agosto 2025 per depositare i rapporti richiesti per i periodi terminati il 31 marzo 2025 e il 30 giugno 2025; il mancato rispetto dell'eccezione potrebbe comportare la cancellazione dalla quotazione, con la possibilità di presentare ricorso a un Hearings Panel. Il deposito elenca il modulo dell'accordo di acquisto come Exhibit 10.1 e la pagina di copertina XBRL interattiva come Exhibit 104.
Celularity Inc. firmó un Series Seed Preferred Stock Purchase Agreement con Defeye, Inc., recibiendo 7,198.630 acciones de Series Seed-2 Preferred Stock a cambio de $2,890,250 en créditos por compras de producto en el marco de su acuerdo de suministro y distribución.
La compañía también informó que Nasdaq le notificó la falta de cumplimiento por no presentar a tiempo su informe trimestral correspondiente al periodo cerrado el 31 de marzo de 2025. La empresa presentó un plan a Nasdaq y le comunicaron que tiene hasta el 31 de agosto de 2025 para presentar los informes requeridos para los periodos cerrados el 31 de marzo de 2025 y el 30 de junio de 2025; el incumplimiento de esta excepción podría llevar a la exclusión de la cotización, con opción de apelación ante un Hearings Panel. El registro enumera el formulario del acuerdo de compra como Exhibit 10.1 y la portada XBRL interactiva como Exhibit 104.
Celularity Inc.는 Defeye, Inc.와 Series Seed 우선주 매매계약(Series Seed Preferred Stock Purchase Agreement)을 체결하고 공급 및 유통 계약에 따른 제품 구매 크레딧 $2,890,250과 교환하여 Series Seed-2 우선주 7,198.630주를 취득했습니다.
회사 측은 또한 Nasdaq로부터 2025년 3월 31일로 종료된 분기보고서를 기한 내 제출하지 않아 불이행 통지를 받았다고 공시했습니다. 회사는 Nasdaq에 계획서를 제출했으며 2025년 3월 31일 및 2025년 6월 30일로 종료된 기간에 대한 필수 보고서를 제출할 수 있도록 2025년 8월 31일까지 기한을 부여받았습니다. 이 예외 기간을 지키지 못하면 상장폐지로 이어질 수 있으며 Hearings Panel에 항소할 수 있습니다. 제출 서류에는 매매계약의 양식이 Exhibit 10.1로, 대화형 XBRL 표지 페이지가 Exhibit 104로 기재되어 있습니다.
Celularity Inc. a conclu un Series Seed Preferred Stock Purchase Agreement avec Defeye, Inc., recevant 7,198.630 actions de Series Seed-2 Preferred Stock en échange de $2,890,250 de crédits d'achat de produits dans le cadre de leur accord de fourniture et de distribution.
La société a également publié que Nasdaq l'a avisée d'une non-conformité pour ne pas avoir déposé en temps voulu son rapport trimestriel pour la période close le 31 mars 2025. La société a soumis un plan à Nasdaq et on lui a indiqué qu'elle disposait jusqu'au 31 août 2025 pour déposer les rapports requis pour les périodes closes le 31 mars 2025 et le 30 juin 2025 ; le non-respect de cette dérogation pourrait entraîner une radiation, avec la possibilité de faire appel devant un Hearings Panel. Le dépôt indique le formulaire de l'accord d'achat comme Exhibit 10.1 et la page de couverture XBRL interactive comme Exhibit 104.
Celularity Inc. schloss eine Series Seed Preferred Stock Purchase Agreement mit Defeye, Inc. ab und erhielt im Austausch für $2,890,250 an Produktkaufguthaben im Rahmen ihrer Liefer- und Vertriebsvereinbarung 7,198.630 Anteile der Series Seed-2 Preferred Stock.
Das Unternehmen gab außerdem bekannt, dass Nasdaq es über eine Nichtkonformität informiert hat, da der Quartalsbericht für den Zeitraum bis zum 31. März 2025 nicht fristgerecht eingereicht wurde. Das Unternehmen reichte einen Plan bei Nasdaq ein und wurde darüber informiert, dass es bis zum 31. August 2025 Zeit hat, die erforderlichen Berichte für die Perioden zum 31. März 2025 und zum 30. Juni 2025 einzureichen; ein Versäumnis der Ausnahme könnte zur Delistung führen, mit der Möglichkeit, vor ein Hearings Panel Berufung einzulegen. Die Einreichung führt die Form des Kaufvertrags als Exhibit 10.1 und die interaktive XBRL-Titelseite als Exhibit 104 auf.
- Entered a material agreement with Defeye resulting in issuance of 7,198.630 Series Seed-2 preferred shares in exchange for $2,890,250 of product purchase credits
- Exhibit filed: Form of Series Seed Preferred Stock Purchase Agreement is included as Exhibit 10.1, providing contract transparency
- Nasdaq noncompliance notice for failure to timely file the quarterly report for the period ended March 31, 2025
- Short compliance window: Nasdaq granted an exception only until August 31, 2025 to file required reports for periods ended March 31 and June 30, 2025; failure may lead to delisting
- Listing risk remains ongoing until the company satisfies Nasdaq's timely filing criteria or successfully appeals any delisting determination
Insights
TL;DR: Company issued 7,198.630 Series Seed-2 preferred shares for $2.89M in product credits and faces Nasdaq filing noncompliance with an Aug 31 deadline.
The issuance to Defeye is a non-cash equity transaction that records $2,890,250 of consideration paid via product purchase credits; the document presents the agreement as material and filed as Exhibit 10.1. Separately, Nasdaq has flagged the company for failure to timely file its quarterly report for the quarter ended March 31, 2025, and granted an exception through August 31, 2025 to file both the March 31 and June 30 reports. This creates a near-term compliance timeline that is material for investors because unresolved noncompliance can result in delisting and procedural appeal steps.
TL;DR: Material securities issuance paired with explicit Nasdaq compliance timeline increases governance and listing-risk focus for stakeholders.
The 8-K discloses a material definitive agreement issuing Series Seed-2 preferred stock in exchange for $2,890,250 of product credits, indicating a contractual monetization of supply obligations through equity. The Nasdaq notice and the granted exception through August 31, 2025 highlight an elevated regulatory and disclosure risk until required reports for the periods ended March 31 and June 30, 2025 are filed. The filing documents the remedies path and the availability of an appeal to a Hearings Panel if Nasdaq issues a delisting notice.
Celularity Inc. ha stipulato un Series Seed Preferred Stock Purchase Agreement con Defeye, Inc., ricevendo 7,198.630 azioni di Series Seed-2 Preferred Stock in cambio di $2,890,250 di crediti per acquisto di prodotto nell'ambito del loro accordo di fornitura e distribuzione.
La società ha inoltre reso noto che Nasdaq l'ha informata della non conformità per il mancato deposito tempestivo del rapporto trimestrale relativo al periodo terminato il 31 marzo 2025. La società ha presentato un piano a Nasdaq e le è stato comunicato che ha tempo fino al 31 agosto 2025 per depositare i rapporti richiesti per i periodi terminati il 31 marzo 2025 e il 30 giugno 2025; il mancato rispetto dell'eccezione potrebbe comportare la cancellazione dalla quotazione, con la possibilità di presentare ricorso a un Hearings Panel. Il deposito elenca il modulo dell'accordo di acquisto come Exhibit 10.1 e la pagina di copertina XBRL interattiva come Exhibit 104.
Celularity Inc. firmó un Series Seed Preferred Stock Purchase Agreement con Defeye, Inc., recibiendo 7,198.630 acciones de Series Seed-2 Preferred Stock a cambio de $2,890,250 en créditos por compras de producto en el marco de su acuerdo de suministro y distribución.
La compañía también informó que Nasdaq le notificó la falta de cumplimiento por no presentar a tiempo su informe trimestral correspondiente al periodo cerrado el 31 de marzo de 2025. La empresa presentó un plan a Nasdaq y le comunicaron que tiene hasta el 31 de agosto de 2025 para presentar los informes requeridos para los periodos cerrados el 31 de marzo de 2025 y el 30 de junio de 2025; el incumplimiento de esta excepción podría llevar a la exclusión de la cotización, con opción de apelación ante un Hearings Panel. El registro enumera el formulario del acuerdo de compra como Exhibit 10.1 y la portada XBRL interactiva como Exhibit 104.
Celularity Inc.는 Defeye, Inc.와 Series Seed 우선주 매매계약(Series Seed Preferred Stock Purchase Agreement)을 체결하고 공급 및 유통 계약에 따른 제품 구매 크레딧 $2,890,250과 교환하여 Series Seed-2 우선주 7,198.630주를 취득했습니다.
회사 측은 또한 Nasdaq로부터 2025년 3월 31일로 종료된 분기보고서를 기한 내 제출하지 않아 불이행 통지를 받았다고 공시했습니다. 회사는 Nasdaq에 계획서를 제출했으며 2025년 3월 31일 및 2025년 6월 30일로 종료된 기간에 대한 필수 보고서를 제출할 수 있도록 2025년 8월 31일까지 기한을 부여받았습니다. 이 예외 기간을 지키지 못하면 상장폐지로 이어질 수 있으며 Hearings Panel에 항소할 수 있습니다. 제출 서류에는 매매계약의 양식이 Exhibit 10.1로, 대화형 XBRL 표지 페이지가 Exhibit 104로 기재되어 있습니다.
Celularity Inc. a conclu un Series Seed Preferred Stock Purchase Agreement avec Defeye, Inc., recevant 7,198.630 actions de Series Seed-2 Preferred Stock en échange de $2,890,250 de crédits d'achat de produits dans le cadre de leur accord de fourniture et de distribution.
La société a également publié que Nasdaq l'a avisée d'une non-conformité pour ne pas avoir déposé en temps voulu son rapport trimestriel pour la période close le 31 mars 2025. La société a soumis un plan à Nasdaq et on lui a indiqué qu'elle disposait jusqu'au 31 août 2025 pour déposer les rapports requis pour les périodes closes le 31 mars 2025 et le 30 juin 2025 ; le non-respect de cette dérogation pourrait entraîner une radiation, avec la possibilité de faire appel devant un Hearings Panel. Le dépôt indique le formulaire de l'accord d'achat comme Exhibit 10.1 et la page de couverture XBRL interactive comme Exhibit 104.
Celularity Inc. schloss eine Series Seed Preferred Stock Purchase Agreement mit Defeye, Inc. ab und erhielt im Austausch für $2,890,250 an Produktkaufguthaben im Rahmen ihrer Liefer- und Vertriebsvereinbarung 7,198.630 Anteile der Series Seed-2 Preferred Stock.
Das Unternehmen gab außerdem bekannt, dass Nasdaq es über eine Nichtkonformität informiert hat, da der Quartalsbericht für den Zeitraum bis zum 31. März 2025 nicht fristgerecht eingereicht wurde. Das Unternehmen reichte einen Plan bei Nasdaq ein und wurde darüber informiert, dass es bis zum 31. August 2025 Zeit hat, die erforderlichen Berichte für die Perioden zum 31. März 2025 und zum 30. Juni 2025 einzureichen; ein Versäumnis der Ausnahme könnte zur Delistung führen, mit der Möglichkeit, vor ein Hearings Panel Berufung einzulegen. Die Einreichung führt die Form des Kaufvertrags als Exhibit 10.1 und die interaktive XBRL-Titelseite als Exhibit 104 auf.
FAQ
What did Celularity (CELUW) disclose about the Series Seed issuance?
Why did Nasdaq notify Celularity (CELUW)?
What deadline did Nasdaq set for Celularity (CELUW) to regain compliance?
What happens if Celularity (CELUW) does not meet Nasdaq's exception terms?
Where can I find the details of the Series Seed Preferred Stock Purchase Agreement?
